Salamanders may hold clues to regrow human limbs

Image
Press Trust of India London
Last Updated : Jun 22 2014 | 12:10 PM IST
Researchers have for the first time identified one of the key molecular pathways that help salamanders regrow their limbs, a breakthrough that could help scientists figure out how to regenerate human organs.
Scientists found that the 'ERK pathway' must be constantly active for salamander cells to be reprogrammed, and hence able to contribute to the regeneration of different body parts.
The team identified a key difference between the activity of this pathway in salamanders and mammals, which helps us to understand why humans can't regrow limbs and sheds light on how regeneration of human cells can be improved.
The study demonstrates that the ERK pathway is not fully active in mammalian cells, but when forced to be constantly active, gives the cells more potential for reprogramming and regeneration.
This could help researchers better understand diseases and design new therapies.
"While humans have limited regenerative abilities, other organisms, such as the salamander, are able to regenerate an impressive repertoire of complex structures including parts of their hearts, eyes, spinal cord, tails, and they are the only adult vertebrates able to regenerate full limbs," lead researcher on the study, Dr Max Yun from the University College London (UCL) Institute of Structural & Molecular Biology said.
"We're thrilled to have found a critical molecular pathway, the ERK pathway, that determines whether an adult cell is able to be reprogrammed and help the regeneration processes. Manipulating this mechanism could contribute to therapies directed at enhancing regenerative potential of human cells," said Yun.
The ERK pathway is a way for proteins to communicate a signal from the surface of a cell to the nucleus which contains the cell's genetic material.
Further research will focus on understanding how this important pathway is regulated during limb regeneration, and which other molecules are involved in the process.
The study was published in the journal Stem Cell Reports.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 22 2014 | 12:10 PM IST

Next Story